Data scientists at the Icahn School of Medicine at Mount Sinai created the model, dubbed “knowledge gap,” to assess the relationship between birth defects, genes and drugs, according to a July 17 press release from Mount Sinai.
Researchers used data produced from the NIH Common Fund programs and datasets from birth defect associations, ReproTox-KG and a semi-supervised learning, to assess approximately 30,000 preclinical small molecule drugs and their potential of crossing the placenta and inducing birth defects.
The analysis found “500 birth-defect/gene/drug cliques,” that could potentially explain molecular mechanisms that could cause drug-induced birth defects.
Researchers warned that the findings are preliminary and that additional research is needed to further validate this.
The full study was published July 17 in Communications Medicine.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
